-+ 0.00%
-+ 0.00%
-+ 0.00%

RANI THERAPEUTICS ANNOUNCES PRECLINICAL DATA DEMONSTRATING BIOEQUIVALENCE OF RT-114, A GLP-1/GLP-2 DUAL AGONIST (PG-102) DELIVERED ORALLY VIA THE RANIPILL® CAPSULE, TO SUBCUTANEOUSLY ADMINISTERED PG-102

Reuters·03/26/2025 20:05:23

Please log in to view news